Loading...
Market
Number of US patients treated with Kebilidi by end of 2025?
2
Resolution / Starting Odds
Less than 100 • 25%
100 to 200 • 25%
201 to 300 • 25%
More than 300 • 25%
PTC Therapeutics' reports or healthcare databases
Story
FDA Approves PTC Therapeutics' Brain-Delivered Gene Therapy Kebilidi for AADC Deficiency
Nov 14, 2024, 01:23 PM
The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics' gene therapy for Aromatic L-amino acid decarboxylase (AADC) deficiency, a potentially fatal enzyme deficiency disorder. This therapy, marketed under the name Kebilidi, is the first brain-delivered gene therapy approved in the United States. The approval was granted following an open-label study involving 13 patients and the use of historical control data.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 10,000 • 25%
10,000 - 20,000 • 25%
20,000 - 30,000 • 25%
More than 30,000 • 25%
Less than 50,000 • 25%
50,000 to 75,000 • 25%
75,000 to 100,000 • 25%
More than 100,000 • 25%
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,001 to 30,000 • 25%
More than 30,000 • 25%
1-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,000 to 15,000 • 25%
More than 15,000 • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
